Takeda files NDA for fixed dose combination of hypertension drug
Discovered by Takeda, Blopress is an angiotensin receptor blocker (ARB) which inhibits action of a vasopressor hormone, angiotensin II. In Japan, it was launched in 1999 and was
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).